vs

Side-by-side financial comparison of Avidity Biosciences, Inc. (RNA) and Tectonic Financial, Inc. (TECTP). Click either name above to swap in a different company.

Tectonic Financial, Inc. is the larger business by last-quarter revenue ($23.0M vs $12.5M, roughly 1.8× Avidity Biosciences, Inc.). Tectonic Financial, Inc. runs the higher net margin — 23.8% vs -1398.3%, a 1422.2% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 17.9%). Tectonic Financial, Inc. produced more free cash flow last quarter ($-17.3M vs $-156.9M). Over the past eight quarters, Tectonic Financial, Inc.'s revenue compounded faster (270.5% CAGR vs 138.5%).

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

Tectonic Financial, Inc. is a US-based diversified financial services provider. It offers core services including wealth management, investment banking, capital markets advisory, and tailored financial solutions. Its key client segments cover high-net-worth individuals, institutional investors, and small to mid-sized enterprises across North America.

RNA vs TECTP — Head-to-Head

Bigger by revenue
TECTP
TECTP
1.8× larger
TECTP
$23.0M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+416.2% gap
RNA
434.0%
17.9%
TECTP
Higher net margin
TECTP
TECTP
1422.2% more per $
TECTP
23.8%
-1398.3%
RNA
More free cash flow
TECTP
TECTP
$139.6M more FCF
TECTP
$-17.3M
$-156.9M
RNA
Faster 2-yr revenue CAGR
TECTP
TECTP
Annualised
TECTP
270.5%
138.5%
RNA

Income Statement — Q3 FY2025 vs Q3 FY2025

Metric
RNA
RNA
TECTP
TECTP
Revenue
$12.5M
$23.0M
Net Profit
$-174.4M
$5.5M
Gross Margin
Operating Margin
-1513.5%
30.6%
Net Margin
-1398.3%
23.8%
Revenue YoY
434.0%
17.9%
Net Profit YoY
-117.0%
15.9%
EPS (diluted)
$-1.27
$0.73

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
RNA
RNA
TECTP
TECTP
Q3 25
$12.5M
$23.0M
Q2 25
$3.8M
$21.6M
Q1 25
$1.6M
$21.8M
Q4 24
$3.0M
$21.4M
Q3 24
$2.3M
$19.5M
Q2 24
$2.0M
$18.6M
Q1 24
$3.5M
$17.6M
Q4 23
$2.2M
$1.7M
Net Profit
RNA
RNA
TECTP
TECTP
Q3 25
$-174.4M
$5.5M
Q2 25
$-157.3M
$4.3M
Q1 25
$-115.8M
$4.5M
Q4 24
$-102.3M
$3.0M
Q3 24
$-80.4M
$4.7M
Q2 24
$-70.8M
$3.1M
Q1 24
$-68.9M
$3.1M
Q4 23
$-60.4M
$3.3M
Operating Margin
RNA
RNA
TECTP
TECTP
Q3 25
-1513.5%
30.6%
Q2 25
-4448.7%
25.9%
Q1 25
-8360.9%
26.0%
Q4 24
-4069.6%
22.1%
Q3 24
-4200.9%
29.1%
Q2 24
-4040.4%
21.5%
Q1 24
-2178.6%
22.2%
Q4 23
-3043.5%
Net Margin
RNA
RNA
TECTP
TECTP
Q3 25
-1398.3%
23.8%
Q2 25
-4089.3%
19.8%
Q1 25
-7360.0%
20.4%
Q4 24
-3439.5%
14.0%
Q3 24
-3441.7%
24.2%
Q2 24
-3461.8%
16.9%
Q1 24
-1943.4%
17.4%
Q4 23
-2756.2%
197.4%
EPS (diluted)
RNA
RNA
TECTP
TECTP
Q3 25
$-1.27
$0.73
Q2 25
$-1.21
$0.55
Q1 25
$-0.90
$0.57
Q4 24
$-0.80
$0.35
Q3 24
$-0.65
$0.58
Q2 24
$-0.65
$0.38
Q1 24
$-0.79
$0.37
Q4 23
$-0.80
$0.40

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
RNA
RNA
TECTP
TECTP
Cash + ST InvestmentsLiquidity on hand
$350.2M
Total DebtLower is stronger
Stockholders' EquityBook value
$1.9B
$119.2M
Total Assets
$2.1B
$1.1B
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
RNA
RNA
TECTP
TECTP
Q3 25
$350.2M
Q2 25
$243.9M
Q1 25
$254.2M
Q4 24
$219.9M
Q3 24
$370.2M
Q2 24
$575.8M
Q1 24
$471.4M
Q4 23
$185.1M
Stockholders' Equity
RNA
RNA
TECTP
TECTP
Q3 25
$1.9B
$119.2M
Q2 25
$1.2B
$114.6M
Q1 25
$1.3B
$111.3M
Q4 24
$1.4B
$113.4M
Q3 24
$1.5B
$112.8M
Q2 24
$1.2B
$110.4M
Q1 24
$830.9M
$108.5M
Q4 23
$500.8M
$106.9M
Total Assets
RNA
RNA
TECTP
TECTP
Q3 25
$2.1B
$1.1B
Q2 25
$1.4B
$997.0M
Q1 25
$1.5B
$910.5M
Q4 24
$1.6B
$863.4M
Q3 24
$1.6B
$847.5M
Q2 24
$1.3B
$777.1M
Q1 24
$951.5M
$777.6M
Q4 23
$628.6M
$677.3M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
RNA
RNA
TECTP
TECTP
Operating Cash FlowLast quarter
$-156.2M
$-17.3M
Free Cash FlowOCF − Capex
$-156.9M
$-17.3M
FCF MarginFCF / Revenue
-1257.6%
-74.9%
Capex IntensityCapex / Revenue
5.7%
0.0%
Cash ConversionOCF / Net Profit
-3.14×
TTM Free Cash FlowTrailing 4 quarters
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
RNA
RNA
TECTP
TECTP
Q3 25
$-156.2M
$-17.3M
Q2 25
$-199.7M
$-32.5M
Q1 25
$-124.8M
$-35.6M
Q4 24
$-99.9M
$-86.6M
Q3 24
$-65.6M
$-22.5M
Q2 24
$-65.0M
$-30.7M
Q1 24
$-70.4M
$-3.2M
Q4 23
$16.5M
$-16.7M
Free Cash Flow
RNA
RNA
TECTP
TECTP
Q3 25
$-156.9M
$-17.3M
Q2 25
$-203.0M
Q1 25
$-128.6M
$-35.6M
Q4 24
$-103.8M
$-86.8M
Q3 24
$-67.3M
$-22.5M
Q2 24
$-65.5M
$-30.7M
Q1 24
$-71.3M
$-3.3M
Q4 23
$15.6M
$-16.7M
FCF Margin
RNA
RNA
TECTP
TECTP
Q3 25
-1257.6%
-74.9%
Q2 25
-5277.1%
Q1 25
-8174.3%
-163.2%
Q4 24
-3491.0%
-406.5%
Q3 24
-2881.8%
-115.0%
Q2 24
-3204.6%
-165.5%
Q1 24
-2012.3%
-18.8%
Q4 23
713.1%
-996.2%
Capex Intensity
RNA
RNA
TECTP
TECTP
Q3 25
5.7%
0.0%
Q2 25
86.9%
0.0%
Q1 25
238.6%
0.0%
Q4 24
131.7%
1.0%
Q3 24
72.9%
0.1%
Q2 24
26.0%
0.3%
Q1 24
25.8%
0.9%
Q4 23
39.4%
0.4%
Cash Conversion
RNA
RNA
TECTP
TECTP
Q3 25
-3.14×
Q2 25
-7.61×
Q1 25
-8.00×
Q4 24
-28.99×
Q3 24
-4.74×
Q2 24
-9.76×
Q1 24
-1.03×
Q4 23
-5.04×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons